RALEIGH, N.C., June 12, 2018 — Spurred by recent regulatory changes and technological innovations, risk-based monitoring (RBM) is a frequent topic of conversation in the pharmaceutical industry. Yet there is little consensus on what RBM really is, how it is implemented, or what role technology plays. In a live webinar on Thursday, June 28 at 11 a.m. EDT / 4 p.m. BST / 5 p.m. CEST), Remarque Systems founder Michael P. Arlotto, PhD will give participants the straight story on RBM.
With its promise to reduce clinical trial costs and timeframes while improving data quality, patient safety, and regulatory compliance, RBM offers many potential benefits for clinical decision makers and CROs of all sizes. In “Debunking the Myths of Risk-Based Monitoring for a New Approach to Quality Management,” Arlotto will address five common myths surrounding RBM:
- RBM is a new requirement of the ICH GCP guidelines
- RBM is just reduced source document verification (SDV)
- Technology alone can solve RBM
- Machine learning RBM solutions are costly and complicated to implement
- RBM cuts clinical investigators out of the loop
Arlotto will also explain why it’s important to incorporate risk monitoring into a broader quality management strategy to set a clinical trial on the path to success. If you’re interested in insightful, actionable tips for implementing an RBM strategy, register now for this informative webinar.
About Michael P. Arlotto, PhD
Michael P. Arlotto is the founder and CEO of Remarque Systems, Inc., a software development company formed in 2015 and dedicated to improving clinical trial safety and efficiency. The company’s first product is Remarque QMS, a comprehensive, purpose-built, SaaS platform to design, deploy & manage Risk-Based Monitoring clinical trials.
About Remarque Systems
Remarque Systems is a provider of risk-based monitoring (RBM) software solutions. Headquartered in Raleigh, N.C., with a development center in Indianapolis, Remarque Systems has developed the first fully integrated workflow system to design, deploy, and manage RBM clinical trials. For more information about Remarque’s RBM solution, please visit the company’s website at www.RemarqueSystems.com or email info@RemarqueSystems.com. Also, follow Remarque on Twitter @RemarqueSystems and LinkedIn.